Keeps Biopharma

At a glance

Keeps Biopharma filed 31 disclosures in the last 12 months, including 4 5% holder and 3 insider. The most recent key filing was on Oct 23: A major holder's stake rose from 22.81% to 22.81% (pledge).

Revenue for 2025 was ₩170B, up 33.4% on 2024. Operating margin was 0.9% against 4.9% a year earlier. Debt was 187% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩134B and operating loss of ₩3.1B.

The 2025 annual report lists 96 employees with an average tenure of 2.9 years and average pay of ₩55.2M, #1208 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩67M each on average. It paid no cash dividend for 2025. ㈜둠밈 and related parties held 24.05% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 22.81% on Oct 23.

From the 2025 annual report

Staff: 96 (64 men, 32 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.3B. Directors and auditors: 5, paid ₩337M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜둠밈 holds 19.92%; with 3 related parties the group holds 24.05% of common shares at year end (from 25.76% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports